Kaleido Biosciences, Inc., a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, has closed an underwritten public offering of 4,750,000 shares of its common stock at a public offering price of US$7.50 per share. In addition, Kaleido has granted the underwriters a 30-day option to purchase up to an additional 712,500 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Kaleido from this offering were approximately US$35.6 million.
Latham & Watkins LLP represented the underwriters in the offering with a capital markets team led by partners Peter Handrinos and Wesley Holmes, with associates Samuel Niles and Emily Henderson. Advice was also provided on regulatory matters by partner Ben Haas, with associate Barrett Tenbarge; on intellectual property matters by partner Alan Tamarelli, with associate Jiqiang Lin; and on tax matters by partner Jocelyn Noll, with associate Joseph Curran.